In fall 2026, the Advarra-facilitated Site-Sponsor Consortium will release a white paper on reducing redundant site training through competency-based, role-based, and reusable training models while aligning with international regulatory guidelines.
This is Part 1 of a three-part series on the site initiation visit (SIV) aspect of training: where redundancy appears, what should remain live and study-specific, and how a better model could separate common training from protocol-specific readiness.
The data shows SIV redundancy is predictable
Clinical research sites have been saying it for years: Too much SIV training repeats what experienced sites already know.
Two Consortium members—a large cancer center and a large multi-therapeutic site network—reviewed training materials from recent Phase II and III trials. Across the 16 trials examined, the same training categories appeared in SIV slides again and again:
- Good Clinical Practice (GCP) and investigator responsibilities
- Safety reporting
- Monitoring expectations
- Documentation and data quality
- Vendor platforms
- Central labs
- Imaging systems
- Other external tools
Some of this content is necessary. But much of it is not study-specific, not sponsor-specific, and not the best use of SIV time.
And the SIV training is long—ranging from 75 to 381 pages per trial in our review! Can you honestly imagine working through materials that arduous? Any professional who has sat through a presentation knows that by slide 40, it can start to feel like running a marathon with no finish line in sight.
The result is a training model that asks sites to repeatedly sit through content they have already mastered, while the truly study-specific issues compete for attention.
What the reviews had in common
The most important finding was that redundancy is predictable.
Trial-agnostic training content occupied 50% to 68% of each deck, with an average of 61% of SIV slides covering topics not specific to the trial. In other words, a substantial portion of SIV training may be teaching content that sites have already encountered elsewhere, or content that could reasonably be trained once instead of study by study.
Overall, the reviews found repeated content in four broad areas.
1. GCP, regulatory, and investigator responsibilities
GCP, regulatory, and investigator responsibility content appeared repeatedly. This included principal investigator (PI) oversight, delegation, informed consent principles, privacy, documentation of training, and core regulatory expectations.
These topics matter. But they’re largely universal. If a site has already been qualified as having appropriate standard operating procedures, training practices, oversight, and quality systems, much of this content isn’t teaching the site something new. It’s re-verifying readiness in the least efficient format possible.
2. Safety reporting
Safety reporting content was one of the clearest areas of duplication. Adverse event (AE) and serious adverse event (SAE) definitions, reporting timelines, pregnancy reporting, death reporting, follow-up requirements, causality, severity grading, and escalation pathways appeared across decks.
Some sponsor-specific differences will always remain. But the core concepts are highly standardizable. The SIV should focus on what is different for this particular protocol, not on re-teaching the basic definitions experienced site staff already know.
3. Monitoring, documentation, and data quality
Monitoring, documentation, and data quality expectations were repeatedly covered. Source documentation; attributable, legible, contemporaneous, original, and accurate (ALCOA) principles; query management; case-report-form completion timelines; protocol deviations; corrective and preventive action (CAPA) expectations; trial file filing; and audit readiness are all essential. But they’re also highly recurring.
Sites do not need to relearn the definition of source documentation from every sponsor. What they need to know is where this study differs, what the sponsor will emphasize, and where operational risk is highest.
4. Vendor and platform training
Vendor and platform training consumed a large share of SIV content. Electronic data capture (EDC) software, randomization and trial supply systems, patient outcome devices, central lab portals, imaging portals, safety distribution systems, and other vendor tools were all represented in the decks.
Yet each of these systems typically comes with its own required training, access instructions, job aids, or certification process. That makes its presence in the SIV hard to justify.
If the site must complete vendor training separately, the SIV should not repeat screenshots of login pages, navigation steps, query workflows, sample shipment instructions, or image-upload procedures. Live SIV time should be reserved for what is unique to the protocol: how these tools affect study conduct, where the operational risks are, and what site staff must do differently for this trial.
SIVs are trying to do too many jobs at once
Taken together, these findings point to a simple conclusion: SIVs are trying to do too many jobs at once.
They’re being used to train sites on universal clinical research expectations, sponsor operating preferences, protocol-specific science, vendor systems, lab workflows, safety reporting, and administrative readiness. The predictable result is information overload.
This matters because poor training design—and excessive length—doesn’t just waste time. It can obscure what’s truly important.
When every slide is treated as equally important, nothing is.
And that’s a real concern when SIV training decks are as lengthy as they are.
Redundancy isn’t just an annoyance. It’s a quality issue.
It’s tempting to treat redundant training as a site burden problem. It is that, but it’s more than that, too.
Redundant training creates noise. Noise reduces attention. Reduced attention increases the chance that critical study-specific information is missed.
When highly qualified sites are repeatedly trained on content they already know, the system isn’t becoming safer. It may be becoming less effective.
A better training model wouldn’t eliminate SIVs. It would make them sharper. It would ask:
- What does every qualified site already know?
- What can be standardized once?
- What can be delivered asynchronously?
- What must be discussed live because it’s protocol-specific, high-risk, or operationally nuanced?
Those questions move SIV training away from slide-count accumulation and toward actual readiness.
What comes next
The first step is recognizing that redundancy isn’t random. It clusters around predictable categories.
The next step is deciding what should remain in the SIV.
Part 2 of this series will focus on what is appropriately study-specific, what should be protected for live discussion, and why complex trials may need more focused SIVs, not longer ones.
Want to learn more? Check out this overview of Advarra’s site collaboration and training solutions or contact us to ask an expert a specific question.
